Uterine artery embolization is minimally invasive, highly effective, well tolerated by most patients. Advantage of this method was uterine sparing, short recovery period, no need for blood transfusion, less anaesthetic complication, etc. Hence Uterine fibroid embolization was an alternate primary treatment to hysterectomy for the management of symptomatic fibroid uterus. Estimates suggest that more that more than 100000 UFE procedures have been performed worldwide. Aim: A prospective interventional study of patients with symptomatic uterine leiomyoma in our hospital subjected to uterine artery embolization. This study is to analyse below parameters of uterine symptomatic leiomyoma 1. Technique 2. Effectiveness 3. Complications 4. Outcome of this technique Materials and Methods: In this study 30 patients having uterine myoma with at least one of the following symptoms are selected: 1. Heavy menstrual bleeding 2. Lower abdominal pain during menstruation (dysmenorrhoea) 3. Urinary symptoms like increased frequency, difficult to micturition. 4. Constipation 5. Lower abdominal heaviness Study Method: It was a prospective interventional study.
The purpose of this study is to analyse the effect of single dose of zoledronic acid in treating postmenopausal osteoporosis Aim of the study To show the significance increase in bmd with zoledronic acid infusion in single dose. Materials Study design -prospective study. Study population -patients attending opd in department of orthopaedics with osteoporosis evaluated by bone mineral density (bmd) scan in govt. kilpaukmedical college hospital. Duration of study -1 year After patients were screened with peripheral BMD densitometry patient were selected then they were subjected to do bmd dexa scan to confirm osteoporosis. Those who were in osteoporotic group were included in our study. Method After patient is evaluated, they were instructed to drink 500ml-1000ml of water for hydration. Then single dose of Zoledronic acid in 100 ml of Normal saline was infused intravenously over 15 mins. Patient were observed for two hours then were discharged with prophylactic Paracetamol tablets.
BACKGROUND Management of endometrial cancer in earlier stages have led to improved Overall Survival (OS) and Progression Free Survival (PFS). Therefore, vaginal brachytherapy (VBT) alone or along with EBRT can be used as adjuvant treatment in intermediate-risk disease (Stage IB G1-2 disease, stage IA G3 disease and stage IC G1-2 disease), with good results in terms of local control and toxicity. METHODS This single institute prospective analytical study included data of 306 patients who presented to Govt. Royapettah Hospital, attached to Govt. Kilpauk Medical College, after surgery, during the period 2012-2018. In this study, patients with endometrial cancer who underwent surgical management and adjuvant vaginal BT were included. This study has taken into consideration the following characteristics-age, histopathology, dose for each fraction, grading scale of toxicity used for each study, and follow-up time in both Treatment and Observed groups. RESULTS Median follow up was 49 months (Range 15-68) in the Treated Group Vs 40 months (range 12-36) in Observed Group. Number of patients who were disease free in the treated group 216 (91%) and in observed group 54 (85 %). Patients with vault recurrence were only 12 (0.5%) in Treated Group and 2 (2.9%) in Observed Group. Patients with pelvic nodes recurrence were only 10 (0.4%) in Treated Group and 2 (2.9%) in Observed Group. Patients with distant metastases were only 12 (0.5%) in the Treated Group and 2 (2.9%) in the Observed Group. CONCLUSIONS HDR endovaginal brachytherapy, with or without External Beam Radiation Therapy provided excellent Overall Survival (OS)/ Progression Free Survival (PFS). The toxicity profile was found to be very minimal.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.